Q-omics provides the consensus-scored TMA7 profile across patient tissues and cancer cell-line models. TMA7 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TMA7 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, TMA7 protein abundance shows 18,784 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KICH, LIHC, and BRCA as cancer lineages where TMA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMA7 survival associations across molecular data types. TMA7 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMA7 RNA expression–survival associations across cancer types. High TMA7 expression shows unfavorable associations in KICH, ACC, KIRC, HNSC, LIHC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for TMA7 RNA expression.
This table summarizes TMA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMA7 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, BLCA, BRCA and CHOL. The LIHC box plot shows higher TMA7 RNA expression in tumor versus normal tissue (log2 FC = +0.919, t-test p < 0.001).
This table shows molecular features associated with TMA7 in patient tissues and cancer cell lines. In patient samples, TMA7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TMA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
